

원저

Effects of *Insamsansa-eum* (*Renshenshanzha-yin*) on Hypercholesterolemia and Analysis of Its Effects according to the Pattern Identification

Seong-Uk Park, Chang-Nam Ko, Woo-Sang Jung,
Sang-Kwan Moon, Ki-Ho Cho, Young-Suk Kim, Hyung-Sup Bae

Department of Cardiovascular & Neurologic Diseases (Stroke Center),
College of Oriental Medicine, Kyung-Hee University, Seoul, Korea.

Backgrounds : Hyperlipidemia is a major cause of cardiovascular disease (CVD). Lowering serum cholesterol levels could reduce the risk of CVD. *Insamsansa-eum* (*Renshenshanzha-yin*, *ISE*), composed of Ginseng Radix and *Crataegii Fructus*, is a new medicine developed to treat hyperlipidemia and CVD.

Objectives : In this study, we intended to explore the clinical effects of *ISE* on patients with hypercholesterolemia, and moreover we also compared its effects according to the pattern identification.

Methods : Subjects were administered *ISE* with the dose of 600 mg three times a day for 4 weeks. Patterns of subjects were identified with diagnostic scoring system for Yin-Yang and the condition of Excess-Deficiency before treatment. Serum lipids were measured at baseline and after 4 weeks of medication.

Results : *ISE* lowered total cholesterol (TC), triglyceride (TG), total lipid (TL), phospholipid(PL) and low density lipoprotein cholesterol (LDL) significantly. Compared with the data of our previous study, it was less effective than Atorvastatin but showed equal lipids-lowering effect to *Chunghyul-dan* (*Qingxue-dan*, *CHD*). In Yang pattern group, *ISE* was less effective in lowering TG and LDL than it was in not-Yang-not-Yinpattern group. On safety assessment, there was no adverse effect, hepatic or renal toxicity.

Conclusions : We suggest that *ISE* is a safe and useful herbal medicine for hypercholesterolemia, and moreover it could be more useful when it is used for patients with not Yang pattern.

Key Words: *Insamsansa-eum* (*Renshenshanzha-yin*, *ISE*), Hypercholesterolemia, Pattern identification

Introduction

Hyperlipidemia, resulting from lipid metabolic changes, is a major cause of cardiovascular disturbance¹⁾, such as atherosclerosis and coronary heart disease. Cardiovascular diseases (CVD) are the most common cause of mortality and morbidity worldwide²⁾. Although several factors, such as cigarette smoking, high-fat diet, high blood pressure, physical inactivity, age and

- 접수 : 2006년 3월 16일 · 논문심사 : 2006년 3월 20일
- 채택 : 2006년 6월 10일
- 교신저자 : Chang Nam Ko, Oriental Medical Doctor (O.M.D.), Ph.D., Associate professor, Stroke and Neurological disorders Center, Kyung-Hee East-West Neo Medical Center, 149 Sangil-dong, Gangdong-gu, Seoul # 134-090, Korea (Republic of) (Tel: 82-2-440-8773, Fax: 82-2-440-9069, E-mail: kcn202@khu.ac.kr)
- This research was supported by the 55th Kyung Hee University Anniversary Research Promotion Fund in 2003.

heredity play a significant role in causing CVD, high blood cholesterol is mainly responsible for the onset of CVD²⁻³). Lowering serum cholesterol levels, by a drug or dietary interventions could reduce the risk of CVD. Therefore, it is worthwhile to develop new safe and effective cholesterol-lowering agents from natural products.

Many herbal medicinal products reported to have an anti-hyperlipidemic effect⁴⁻¹¹). *Insamsansa-eum* (*Renshenshanzha-yin*, ISE) is a combinatorial drug consisting of *Ginseng Radix* and *Crataegii Fructus*. Many reports from clinical and experimental studies suggested that ginseng and Hawthorn (*Crataegus*) fruits may have an antihyperlipidemic effect¹²⁻¹⁶) and ISE showed significant antioxidant and lipid-lowering effects in our previous experimental study (Y. S. Kim et al., unpublished

observations, 2004).

Therefore, in the present study we intended to explore the clinical effects of ISE, a new medicine developed to treat hyperlipidemia, on humans with hypercholesterolemia, and moreover we also compared its effects according to the pattern identification.

Subjects and Methods

Subject selection

Subjects were recruited from the patients visiting cardiovascular center, Kyung Hee University Kangnam Korean Hospital between November 2003 and December 2004.

Inclusion criteria was that serum total cholesterol was more than 240 mg/dL.

Table 1. Composition of *Insamsansa-eum*

Constitute herbs	Scientific name	Mass (g/capsule)
<i>Ginseng Radix</i>	<i>Panax ginseng</i> C. A. MEYER	1
<i>Crataegii Fructus</i>	<i>Crataegus pinnatifida</i> BGE.	3
Total		4

Table 2. Diagnostic scoring system for *Yin-Yang*

A: <i>Yang</i> indicating signs		B: <i>Yin</i> indicating signs	
Feeling of heat inside, desire for thin clothes, sweating in the region of the neck and head	+20	Feeling of cold, desire for warm clothes	-20
Desire for cold water, cold liquids	+10	Desire for heating, hot bath, etc	-20
Red face, inflamed sclera	+10	Pale face	-5
BT 36.7°C and above	+10	BT 36.2°C and below	-10
Red tip of the tongue	+10	Cold of the neck, back and lumbosacral region	-10
Pulsus frequens	+5	Subj. a. obj. coldness of limbs	-5
Pulsus superficialis	+5	Pulsus profundus et inequalis	-5
Distress of the chest and resistance tender on pressure of the right subcostal region	+5	Impaired hearing, articulation of words not clear	-5
Diarrhea accompanied by burning sensation of the anus	+5	Diarrhea without burning sensation of the anus	-5
Burning sensation during micturition, strong stream	+10	Only faint smell of the feces	-5
Strong smell of feces	+5	Pollakisuria, weak stream	-10

A total score of more than +35 points indicates a condition of *Yang*.

A total score of more than -35 points indicates a condition of *Yin*.

Table 3. Diagnostic scoring system for the condition of *Excess or Deficiency*

Shining eyes, strong voice	+5	Dull eyes, weak voice, fatigue, Ki-deficiency	-5
Pulse of excess-type	+20	Pulse of deficiency-type	-10
Marked increased abdominal tension	+10	Marked reduction of abdominal tension	-10
Physiological skin color	+5	Pathological skin color	-5
Eczema, induration, pain	+10	Sweating easily without physical exertion	-5
Severe pain(chest, abdomen)	+20	Night sweat	-10
Painful tension of muscles	+10	Sound of fluctuating liquid in the stomach	-20
Offensive smell of feces, constipation	+10	No constipation, only faint smell of feces	-10
Subcutaneous edema of the abdominal skin with impressions of examiner's fingers quickly extinguished	+10	Subcutaneous edema of the abdominal skin with impressions of examiner's fingers slowly extinguished	-10
Steerhorn stomach	+10	Ptosis of organs/stomach	-20

Mild symptoms are scored with half the corresponding points. A total score of more than +30 points indicates a condition of *Excess*, a total score of -30 points is typical for a condition of *Deficiency*. A total score less than +30 or -30 describes the status of KI between *Excess and Deficiency*.

Exclusion criteria included¹⁾ diabetes mellitus,²⁾ hepatic or renal diseases³⁾, cardio or cerebral vascular diseases within 3 months⁴⁾, patients who had taken anti-hyperlipidemic agents, or steroids within 6 months, and⁵⁾ alcoholic abusers.

Informed consents were obtained from all subjects after being given a full explanation of the study.

Materials

Insamsansa-eum (*Renshenshanzha-yin*, ISE) isa capsulated water extract (300 mg per one capsule) of Ginseng Radix and Crataegii Fructus (Table 1). Each herbal medicine was extracted twice with boiling water for 2 h. These extracts were filtered and evaporated in a rotary vacuum evaporator and then finally lyophilized with a freezing dryer. To standardize the quality of ISE, ginsenoside Rg1 in Ginseng Radix was quantitatively assayed according to the previous methods¹⁷⁾.

Study protocol

Subjects'general characteristics were recorded and diagnosis were confirmed when the World Health Organization Diagnostic Criteria were fulfilled

or they had prior treatment history. Patterns of subjects were identified with diagnostic scoring system for Yin-Yang and the condition of Excess-Deficiency¹⁸⁾ (Table 2, 3) before treatment.

Subjects were administered ISE with the dose of 600 mg three times a day for 4 weeks. Any dietary advice was not given to the subjects, so they could maintain their life style on diet and exercise.

Serum lipids including total cholesterol (TC), triglyceride (TG), total lipid (TL), phospholipid (PL), high density lipoprotein (HDL) cholesterol, and low density lipoprotein (LDL) cholesterol were measured at baseline and after 4 weeks of medication. For each subject, 10-15 mL of blood was collected in blood collection tubes containing heparin after overnight fasting, and the analysis of serum lipids was performed using an enzymatic method (Hitachi 7600-110, Japan).

Any possible adverse effect was monitored by physical examination during the treatment period. Hepatic and renal toxicity were assessed by Aspartate transaminase (AST), Alanine transaminase (ALT), Blood urea nitrogen (BUN), and Creatinine (Cr).

Table 4. Subjects' general Characteristics

		(n=20)
Male, n (%)		9(45)
Age, y (range)		47±13.2(28-69)
Coronary artery disease, n (%)		0(0)
Hypertension, n (%)		5(25)
Total Cholesterol		267.7±13.8
<i>Yin-Yang</i> pattern identification	<i>Yin</i> , n (%)	0(0)
	<i>Yang</i> , n (%)	8(40)
	<i>Not-Yin-not-Yang</i> , n (%)	12(60)
<i>Deficiency-Excess</i> pattern identification	<i>Deficiency</i> , n (%)	4(20)
	<i>Excess</i> , n (%)	8(40)
	<i>Not-Deficiency-not-Excess</i> , n (%)	8(40)

Statistical analysis

All results are expressed as mean ± SD unless otherwise stated. Data were analyzed by one-way ANOVA, paired t-test and independent t-test. A value of P<0.05 was considered significant. All calculation was performed by SPSS for windows, version 11.5 (SPSS Inc., Chicago, Illinois, USA).

Results

Initial subjects' characteristics

The characteristics of the subjects are summarized in Table 4. At first, 25 subjects were recruited but 5 subjects dropped out during the study. Therefore, 20 subjects were included in the final analysis. In Yin-Yang pattern identification, 8 subjects showed Yang pattern and 12 subjects showed not-Yin-not-Yang. 4 subjects showed Deficiency pattern, 8 showed Excess and 8 showed not-Deficiency-not-Excess in Deficiency-Excess pattern identification.

Lipid lowering effect of ISE

ISE lowered TC, TL, TG, PL, and LDL

significantly. But, HDL was not lowered significantly (Table 5).

Comparison of lipid-lowering effects among the groups

This study is not a case-controlled trial so we compared ISE's lipid-lowering effect with the data of our previous study¹⁹⁾. There were no significant differences in the subjects' general characteristics and the baseline assessment of lipid levels among three groups (data not shown). ISE was less effective than Atorvastatin in lowering TC and LDL. But, there were no significant differences in lipids-lowering effects between ISE and Chunghyul-dan (Qingxue-dan, CHD) (Table 6).

Changes of serum lipids according to the pattern identification

In Yang pattern group, ISE was less effective in lowering TG and LDL than it was in not-yang-not-Yin pattern group (Table 7). But, in Excess-Deficiency pattern identification, there were no significant differences in ISE's lipids-

lowering effects among the groups (data not shown).

Safety assessment

There was no clinical adverse effect during 4 weeks of medication. Table 8 shows there was no significant elevation of ALT, AST, BUN, and Cr.

Discussion

ISE is a new medicine developed to treat hyperlipidemia and CVD. In this study, ISE significantly lowered TC, TL, TG, PL, and LDL

after 4 weeks of treatment. The mechanism by which ISE decreases serum cholesterol remains unclear. Serum cholesterol can be lowered at several metabolic points including decreased synthesis, activation of LDL receptors, inhibition on absorption of dietary cholesterol, and conversion of cholesterol to bile acids. It was previously reported that ginseng may decrease blood cholesterol levels by increasing cholesterol excretion through bile acid formation²⁰⁻²¹⁾, and increase LDL receptors by promoting the synthesis of LDL receptors in rats²²⁾. Muwalla and Abuirmmeileh reported that 3-hydroxy-3-

Table 5. Lipids-lowering Effects of *Insamsansa-eum*

(mg/dL)	Baseline	4 weeks
TC	267.7±13.8	238.8±23.1**
TL	722.9±95.0	681.6±110.8**
TG	154.6±43.7	134.1±34.8*
PL	290.9±26.0	271.6±26.5**
HDL	62.4±11.1	61.8±9.5
LDL	163.8±42.0	150.2±20.0*

Values are mean ± standard deviation.

TC, TG, TL, PL, HDL, and LDL are total cholesterol, triglyceride, total lipid, phospholipids, high density lipoprotein cholesterol, and low density lipoprotein cholesterol, respectively.

* and ** are P<0.05 and 0.01 by paired t-test vs. baseline

Table 6. Comparison of the Lipid-lowering Effects between the Groups

(mg/dL)	Changes during 4 weeks		
	<i>Insamsansa-eum</i>	<i>Chunghyul-dan</i>	Atrovastatin
TC	-28.9±29.1	-14.5±31.4	-83.8±28.2*
TL	-41.3±56.7	-26.2±158.3	-86.4±293.9
TG	-20±33.2	6.2±118.0	27.8±226.8
PL	-19.3±28.1	-13.9±31.6	-39.6±38.4
HDL	-0.6±6.4	-3.57±6.61	0.08±6.54
LDL	-13.6±40.7	-12.1±30.6	-64.3±22.8*

Values are mean ± standard deviation.

TC, TG, TL, PL, HDL, and LDL are total cholesterol, triglyceride, total lipid, phospholipids, high density lipoprotein cholesterol, and low density lipoprotein cholesterol, respectively.

* is P<0.01 by independent t-test vs. *Insamsansa-eum* group




Fig. 1. Hypothesis of the relationship between the name of disease used in modern western medicine and the pattern in the system of oriental medicine.

methylglutaryl coenzyme A (HMG-CoA) reductase activity was significantly lowered by ginseng, which shows the mechanism of the hypocholesterolemic action of ginseng involves the suppression of cholesterol biosynthesis¹². Hawthorn (*Crataegus*) fruit was reported to increase LDL-receptor activity of hepatic membrane in rats²³. In addition to the activation of LDL receptors, it was also reported to increase excretion of bile acids through up-regulation of hepatic cholesterol 7 α -hydroxylase activity, and inhibit cholesterol absorption through down-regulation of intestinal acyl CoA: cholesterol acyltransferase activity¹⁴. Based on the studies reported, it was thought that those action mechanisms of *Ginseng Radix* and *Crataegii Fructus* on lipid metabolism might be involved in the present study.

This study is not a case-controlled trial. Therefore, we compared ISE's lipid-lowering effect with the data of our previous study¹⁹. It was less effective than Atorvastatin but showed equal lipids-lowering effect with CHD. Although Atorvastatin is highly effective, it has been reported to have several kinds of side effects²⁴⁻²⁶. Therefore, it is worthy to develop new effective agents from natural products, which are generally safer than conventional chemical agents. And moreover *Ginseng Radix* and *Crataegii Fructus* have been reported to improve cardiac function and decrease peripheral resistance²⁷⁻³¹. Thus we could expect ISE's additional effect, preventing chronic heart failure or treating early stage of chronic heart failure.

In the present study, ISE's lipid-lowering effect

Table 7. Changes of serum lipids according to the pattern identification

(mg/dL)	Changes during 4 weeks	
	Yang pattern	Not Yin not Yang pattern
TC	-18.8±23.8	-35.7±31.3
TL	-21.6±54.9	-54.5±56.2
TG	-2±27.8	-32.8±31.6*
PL	-10.5±27.9	-25.2±27.8
HDL	-2.3±2.9	0.5±7.9
LDL	-10.4±51.1	-29.6±22.4*

Values are mean ± standard deviation.

TC, TG, TL, PL, HDL, and LDL are total cholesterol, triglyceride, total lipid, phospholipids, high density lipoprotein cholesterol, and low density lipoprotein cholesterol, respectively.

* is P<0.05 by independent t-test vs. Yang pattern group

Table 8. Safety assessment

(mg/dL)	Medication		P-value*
	Before	After	
AST(U/L)	19.0±4.7	16.7±3.9	N.S
ALT(U/L)	19.3±9.0	17.8±9.1	N.S
BUN(mg/dL)	14.8±5.2	12.4±2.5	N.S
Cr(mg/dL)	0.9±0.3	0.9±0.2	N.S

Values are mean ± deviation.

AST: aspartate transaminase, ALT: alanine transaminase, BUN: blood urea nitrogen, Cr: creatinine

*: tested by paired t-test.

was compared according to the pattern identification. In Yang pattern group, ISE was less effective in lowering TG and LDL than it was in not-yang-not-Yin pattern group (Table 7). Traditional oriental medicine has used Ginseng Radix and Crataegii Fructus, especially Ginseng Radix, to treat patients with Yinpattern. So this result is thought in agreement with the tradition of oriental medicine. It appears that there are no direct links between the name of disease used in modern western medicine and the pattern (the condition of the patient) in the system of oriental medicine. But when we treat a disease especially with herbal medicine, it is thought to be more effective and safe when diagnosis is made by not only the name of disease but also the pattern identification (Figure 1). For example, when hyperlipimemia is treated, ISE could be used for patients with Yin pattern and CHD, composed of Scutellariae Radix, Coptidis Rhizoma, Phellodendri Cortex, Gardeniae Fructus, and Rhei Rhizoma, could be used for patients with Yang pattern.

There are two limitations in this study. First, this study is small and not a case-controlled trial so we can not make a concrete conclusion. Even though we compared ISE's effect with the data of our previous study, large randomized controlled

trial should be followed. Secondly, treating a disease according to the pattern identification is a kind of hypothesis that should be tested. And there are many kinds of pattern identifications in oriental medicine. Further studies using various pattern identifications will be necessary to test this hypothesis.

In conclusion, we suggest that ISE is a safe and useful herbal medicine for hypercholesterolemia, and moreover it could be more useful when it is used for patients with not Yang pattern.

References

1. Chobanian AV. Single risk factor intervention may be inadequate to inhibit atherosclerosis progression when hypertension and hypercholesterolemia coexist. *Hypertension*. 1991; 18: 1301.
2. Libby P, Theroux P. Pathophysiology of coronary artery disease. *Circulation*. 2005 ; 111(25): 3481-8.
3. Scandinavian Simvastatin Survival Study (4S) group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. *Lancet*. 1994; 344: 1383-9.
4. Choi JS. Antihyperlipidemic effect of flavonoids from *Prunus Davidiana*. *Journal*

- of Natural Products. 1991; 54: 2184.
5. Chen CC, Liu LK, Hsu JD, Huang HP, Yang MY, Wang CJ. Mulberry extract inhibits the development of atherosclerosis in cholesterol-fed rabbits. *Food Chemistry*. 2005; 91(4): 601-7.
 6. Shukla R, Gupta S, Gambhir JK, Prabhu KM, Murthy PS. Antioxidant effect of aqueous extract of the bark of *Ficus bengalensis* in hypercholesterolaemic rabbits. *Journal of Ethnopharmacology*. 2004; 92: 4751.
 7. Abe I, Seki T, Noguchi H, Kashiwada Y. Galloyl esters from rhubarb are potent inhibitors of squalene epoxidase, a key enzyme in cholesterol biosynthesis. *Planta Med*. 2000; 66(8): 753-6.
 8. Iijima OT, Takeda H, Matsumiya T. Effects of San'o-shashin-to on the antioxidative mechanism in spontaneous familial hypercholesterolaemic rabbits. *Pharmacol Res*. 2000; 41(2) : 137-41.
 9. Kimura Y, Okuda H, Taira Z, Shoji N, Takemoto T, Arichi S. Studies on *Scutellariae radix*. IX. New component inhibiting lipid peroxidation in rat liver. *Planta Med*. 1984 ; 50(4): 290-5.
 10. Lee YJ. The effects of fraction obtained from *Rhei Rhizoma* on the blood lipids in hypercholesterol rats. *Journal of Korean Herbology*. 2000; 15(2): 87-93.
 11. Roh HS, Koh WK, Kim WJ, Park KK, Cho YH, Park HS. Antihyperlipidemic activity of *Scutellaria baicalensis* Georg., *Coptidis japonica* Makino and *Rhei koreanum* Nakai on experimental hyperlipidemia in rats. *Journal of Korean Pharmaceutical Sciences*. 1996; 26(3): 215-9.
 12. Muwalla MM, Abuirmmeileh NM. Suppression of avian hepatic cholesterogenesis by dietary ginseng. *J. Nutr. Biochem*. 1990; 1: 51821.
 13. Zheng X, Yan Y. The effect of ginsenosides of ginseng stem and leaf (GSL) on the lipid regulation and lipid peroxidation in chronic hyperlipidemic rabbits. *Zhongguo Yaolixue Tonbao*. 1991; 7: 1106.
 14. Zhang ZS, Ho WKK, Huang Y, Chen ZU. Hypocholesterolemic activity of hawthorn fruit is mediated by regulation of cholesterol 7α -hydroxylase and acyl CoA: cholesterol acyltransferase. *Food Research International*. 2002; 35(9): 885-91.
 15. Chen JD, Wu YZ, Tao ZL, Chen ZM, Liu XP. Hawthorn (*Shan Zha*) drink and its lowering effect on blood lipid levels in humans and rats. *World Review of Nutrition and Dietetics*. 1995; 77: 14754.
 16. von Eiff M. Hawthorn/Passion flower extract and improvement in physical capacity of patients with dyspnea Class II of the NYHM functional classification. *Acta Therapeutica*. 1994; 20: 4766.
 17. Hayakawa J, Noda N, Yamada S, Mikami E, Uno K. Studies on physical chemical quality evaluation of crude drugs preparations. III. Analysis of gardenia fruits and its preparations. *Yakugaku Zasshi*. 1985; 105 : 996-1000.
 18. Terasawa K. Diagnostic scoring system for Yin-Yang. Diagnostic scoring system for the condition of excess or deficiency: *Kampo Japanese-oriental medicine Insights From Clinical Cases*. Tokyo: K.K. Standard McIntyre. 1993: 82-86.
 19. Cho KH, Kang HS, Jung WS, Park SU, Moon SK. Efficacy and Safety of *Chunghyul-*

- dan (Qingwie-dan) in Patients with Hypercholesterolemia. *Am. J. Chin. Med.* 2005; 33(2) : 241-8.
20. Yamamoto M, Kumagai A. Long term ginseng effects on hyperlipidemia in man with further study of its actions on atherogenesis and fatty liver rats: Proceedings of the 4th International Ginseng Symposium at Korea Ginseng & Tobacco Research Institute. 1984 : 1320.
21. Joo CN. The preventive effect of Korean ginseng saponins on aortic atheroma formation in prolonged cholesterol fed rabbits: Proceedings of the 3rd International Ginseng Symposium at Korea Ginseng & Tobacco Research Institute. 1980: 2736.
22. Yokozawa T, Kobayashi T, Kawai A, Oura H, Kawashima Y. Hyperlipidemia-improving effects of ginsenoside-Rb₂ in cholesterol-fed rats. *Chem. Pharm. Bull.* 1985; 33: 7229.
23. Rajendran S, Deepalakshmi PD, Parasakthy K, Devaraj H, Devaraji SN. Effect of tincture of *Crataegus* on the LDL-receptor activity of hepatic plasma membrane of rats fed an atherogenic diet. *Atherosclerosis.* 1996; 123 : 23541.
24. Hendriks F., Kooman JP, van der Sande FM. Massive rhabdomyolysis and life threatening hyperkalaemia in a patient with the combination of cerivastatin and gemfibrozil. *Nephrol Dial Transplant.* 2001; 16(12): 2418-19.
25. Scheen AJ. Fatal rhabdomyolysis caused by cerivastatin. *Rev Med Liege.* 2001; 56(8): 592-4.
26. Alexandridis G., Pappas GA, Elisaf MS. Rhabdomyolysis due to combination therapy with cerivastatin and gemfibrozil. *Am J Med.* 2000; 109(3): 261-2
27. Ding DZ, Shen TK, Cui YZ. Effects of red ginseng on the congestive heart failure and its mechanism. *Chung Kuo Chung His I Chieh Ho Tsa Chih.* 1995; 15: 325-7.
28. Feng PF, QinNP, Qiao Q. Clinical and experimental study of improving left ventricular diastolic function by total saponins of panax notoginseng. *Chung Kuo Chung His I Chieh Ho Tsa Chih.* 1997; 17: 714-7.
29. Schussler M, Holz J, Fricke U. Myocardial effects of flavonoids from *Crataegus* species. *Arzneimittelforschung.* 1995; 45: 842-5.
30. Weihmayr T, Ernst E. Therapeutic effectiveness of *Crataegus*. *Fortschr Med.* 1996; 114: 27-9.
31. Weikl A, Assmus KD, Neukum-Schmidt A, Schmitz J, Zapfe G, Noh HS et al. *Crataegus* Special Extract WS 1442. Assessment of objective effectiveness in patients with heart failure (NYHA II). *Fortschr Med.* 1996; 114 : 291-6.